AAP
SUPN icon

Arax Advisory Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Arax Advisory Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
2,189
+1,972
+909% +$94.7K ﹤0.01% 2719
2026
Q1 		$11.2K Sell
217
-240
-53% -$12.2K ﹤0.01% 2385
2025
Q4 		$22.7K Sell
457
-3,479
-88% -$169K ﹤0.01% 2045
2025
Q3 		$188K Buy
3,936
+3,868
+5,688% +$156K ﹤0.01% 1284
2025
Q2 		$2.14K Buy
68
+26
+62% +$833 ﹤0.01% 2552
2025
Q1 		$1.38K Sell
42
-80
-66% -$2.83K ﹤0.01% 2199
2024
Q4 		$4.41K Hold
122
– – ﹤0.01% 1784
2024
Q3 		$3.8K Sell
122
-17
-12% -$531 ﹤0.01% 1828
2024
Q2 		$3.72K Buy
139
+104
+297% +$3.01K ﹤0.01% 1718
2024
Q1 		$1.19K Sell
35
-37
-51% -$1.1K ﹤0.01% 1125
2023
Q4 		$2.08K Buy
72
+5
+7% +$133 ﹤0.01% 1010
2023
Q3 		$1.85K Hold
67
– – ﹤0.01% 1022
2023
Q2 		$2.02K Hold
67
– – ﹤0.01% 1000
2023
Q1 		$2.43K Hold
67
– – ﹤0.01% 978
2022
Q4 		$2.39K Buy
67
+23
+52% +$799 ﹤0.01% 920
2022
Q3 		$1K Hold
44
– – ﹤0.01% 1154
2022
Q2 		$1K Hold
44
– – ﹤0.01% 1120
2022
Q1 		$1K Hold
44
– – ﹤0.01% 1098
2021
Q4 		$1K Buy
+44
New +$1.33K ﹤0.01% 1084

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Arax Advisory Partners's SUPN Position: Q2 2026 in Review

Arax Advisory Partners increased its Supernus Pharmaceuticals (SUPN) stake by 909% in Q2 2026, buying an estimated $94.7K and bringing the position to 2,189 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #2719.

Arax Advisory Partners first reported a position in SUPN in Q4 2021 and has held it in 19 quarters since. The position peaked at $188K in Q3 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Arax Advisory Partners held 2,189 shares of Supernus Pharmaceuticals worth $102K as of Q2 2026.
  • Arax Advisory Partners bought 1,972 Supernus Pharmaceuticals shares in Q2 2026, an estimated $94.7K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2719 holding.
  • Arax Advisory Partners first reported a position in Supernus Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Arax Advisory Partners's Supernus Pharmaceuticals position peaked at $188K in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.